Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M versus TRAVASOL 8 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M versus TRAVASOL 8 5 IN PLASTIC CONTAINER.
AMINOSYN 3.5% M vs TRAVASOL 8.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a crystalline amino acid solution providing essential and nonessential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for anabolic processes and helps correct negative nitrogen balance.
TRAVASOL 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral nutrition.
Intravenous infusion; typical adult dose: 1 to 1.5 g amino acids/kg/day (equivalent to 28.6 to 42.9 mL/kg/day of 3.5% solution). Administer via central or peripheral line at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous administration as total parenteral nutrition: typical adult dose is 8.5% amino acid solution at 0.8-1.5 g protein/kg/day, infused continuously or cyclically.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is typically 0.5-2 hours in patients with normal renal and metabolic function, reflecting rapid uptake and metabolism by tissues. In hepatic or renal impairment, half-life may be prolonged due to decreased clearance.
Not applicable; constituent amino acids have individual half-lives (e.g., 0.5–2 hours for most L-amino acids) but overall elimination follows zero-order kinetics during continuous infusion. Clinically, infusion rate determines steady-state concentrations.
Amino acids in Aminosyn 3.5% M are primarily eliminated via metabolism (utilization for protein synthesis, energy, and other metabolic pathways). Minimal amounts are excreted unchanged in urine (less than 5% of infused amino acids) via glomerular filtration. There is no significant biliary or fecal elimination.
Renal elimination of nitrogenous waste products (urea, ammonia) derived from amino acid metabolism; biliary/fecal excretion negligible. In healthy adults, >90% of infused amino nitrogen is ultimately excreted as urea in urine.
Category C
Category C
Amino Acid Solution
Amino Acid Solution